Translating costimulation blockade to the clinic: lessons learned from three pathways
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: As the recognition that costimulatory signals are critical for optimal T‐cell activation, proliferation, and differentiation, there has been an explosion in the study of costimulatory molecules and their roles in enhancing anti‐donor T‐cell responses following transplantation. Here, we focus on the bench‐to‐beside translation of blocking agents designed to target three critical costimulatory pathways: the CD28/CD80/CD86 pathway, the CD154/CD40 pathway, and the lymphocyte function associated antigen‐1/intercellular adhesion molecule pathway. While blockade of each of these pathways proved promising in inhibiting donor‐reactive T‐cell responses and promoting long‐term graft survival in murine models of transplantation, the progression of development of therapeutic agents to block these pathways has each taken a slightly different course. Both logistical and biological pitfalls have accompanied the translation of blockers of all three pathways into clinically applicable therapies, and the development of costimulatory blockade as a substitute for current standard‐of‐care calcineurin inhibitors has by no means reached completion. Collaboration between both the basic and clinical arenas will further propel the development of costimulation blockers currently in the pipeline, as well as of novel methods to target these critical pathways during transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“These results are particularly important given the tragic results of a phase I clinical trial in humans earlier this year (26), where six healthy volunteers experienced a systemic inflammatory response following administration of an agonistic anti-CD28 mAb (26).”
ResultRegulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28
Fraser, J. D., Irving, B. A., Crabtree, G. R., & Weiss, A. (1991) · Science · doi:10.1126/science.1846244 · Cited by 641 · cited 5×
“Signaling through CD28 increases transcription and messenger RNA (mRNA) stability of interleukin-2 (IL-2) (5, 6), elevates the expression of anti-apoptotic molecules such as B-cell leukemia ⁄ lymphoma x (Bcl-XL) (7), and decreases the threshold level of T-cell receptors (TCRs) required for activation (8).”
BackgroundInfluentialHeterologous immunity provides a potent barrier to transplantation tolerance
Adams, A. B., Williams, M. A., Jones, T. R., Shirasugi, N., Durham, M. M., Kaech, S. M., Wherry, E. J., Onami, T., Lanier, J. G., Kokko, K. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317477 · Cited by 616 · cited 3×
“costimulation blockade-based tolerance regimen effectively prevented skin graft rejection in naive mice, mice that had been previously infected with one, two, or three different viruses demonstrated increasing resistance to the induction of tolerance by costimulation blockade (114).”
BackgroundSelf-citationStebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 1×
“hyperactivated and secrete inflammatory cytokines (27).”
The Roles of CD28 and CD40 Ligand in T Cell Activation and Tolerance
Howland, K. C., Ausubel, L. J., London, C. A., & Abbas, A. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4465 · Cited by 173
Interferon-γ Acts Directly on Rejecting Renal Allografts to Prevent Graft Necrosis
Halloran, P. F., Afrouzian, M., Ramassar, V., Urmson, J., Zhu, L.-F., Helms, L. M. H., Solez, K., & Kneteman, N. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63960-0 · Cited by 78
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation
Kim, C. H., Park, J., & Kim, M. (2014) · Immune Network · doi:10.4110/in.2014.14.6.277 · Cited by 704
“differentiation and effector function (15-17).”
Yazdanbakhsh, K., Ware, R. E., & Noizat-Pirenne, F. (2012) · Blood · doi:10.1182/blood-2011-11-327361 · Cited by 404
Sharpe, A. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00784.x · Cited by 357
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches
Diehl, R., Ferrara, F., Müller, C., Dreyer, A. Y., McLeod, D. D., Fricke, S., & Boltze, J. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.39 · Cited by 174
Metadata
- Authors
- Ford, M. L., & Larsen, C. P.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2009-04-21
- Volume
- 229
- Issue
- 1
- Pages
- 294-306
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2125758525
- Cited by
- 123
- References
- 7
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating costimulation blockade to the clinic: lessons learned from three pathways. https://app.cochat.ai/papers/10.1111/j.1600-065x.2009.00776.x
- The paper
- Ford, M. L., & Larsen, C. P. (2009). Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2009.00776.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.